MADISON, Wis., Oct. 25, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today shared data from modeling analyses that demonstrate Cologuard (mt-sDNA), with its included patient navigation ...

MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present late-breaking ...

MADISON, Wis., Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal ...

Note: specificity including non-advanced findings includes colonoscopy results that were negative for cancer or advanced precancer upon histopathological review; specificity including no findings ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...

With March serving as National Colorectal Cancer Awareness Month, there’s no better way to play a role than by simply to help raise awareness. That’s the mission this week’s Cologuard Classic by Exact ...

Anne grew up in a small farm town in southeast Nebraska, where her upbringing was filled with lessons on problem solving, teamwork and the importance of giving back. These qualities have carried her ...

Repositioning to better reach the elusive 45- to 50-year-old segment of potential colon cancer screening patients, Cologuard ads have replaced people singing a version of the Sinatra standard “My Way” ...

American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for ...